Sign in or create an account to add this stock to your watchlist.
About Acer Therapeutics (NASDAQ:ACER)
Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100
Debt
Debt-to-Equity RatioN/A
Current Ratio5.34
Quick Ratio5.34
Price-To-Earnings
Trailing P/E Ratio-4.73
Forward P/E Ratio-7.72
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.90 million
Price / Sales47.12
Cash FlowN/A
Price / CashN/A
Book Value$2.48 per share
Price / Book7.35
Profitability
EPS (Most Recent Fiscal Year)($3.84)
Net Income$-14,190,000.00
Net MarginsN/A
Return on Equity-86.30%
Return on Assets-76.75%
Miscellaneous
Employees6
Outstanding Shares7,500,000
Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions
What is Acer Therapeutics' stock symbol?
Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."
How were Acer Therapeutics' earnings last quarter?
Acer Therapeutics (NASDAQ:ACER) released its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.16. View Acer Therapeutics' Earnings History.
What price target have analysts set for ACER?
3 analysts have issued 1-year price targets for Acer Therapeutics' shares. Their predictions range from $50.00 to $70.00. On average, they expect Acer Therapeutics' share price to reach $60.00 in the next twelve months. View Analyst Ratings for Acer Therapeutics.
Who are some of Acer Therapeutics' key competitors?
Some companies that are related to Acer Therapeutics include Progenics Pharmaceuticals (PGNX), Cara Therapeutics (CARA), TIGENIX/S (TIG), Insys Therapeutics (INSY), Achaogen (AKAO), Zealand Pharma (ZEAL), Evelo Biosciences (EVLO), Achillion Pharmaceuticals (ACHN), Mersana Therapeutics (MRSN), Isotechnika Pharma (AUPH), Clementia Pharmaceuticals (CMTA), Concert Pharmaceuticals (CNCE), Cytokinetics (CYTK), Obseva (OBSV) and Evolus (EOLS).
Who are Acer Therapeutics' key executives?
Acer Therapeutics' management team includes the folowing people:
- Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 42)
- Mr. Harry S. Palmin, Chief Financial Officer (Age 48)
- Mr. Jefferson Davis, Acting Chief Bus. Officer (Age 51)
- Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 53)
- Ms. Kim Tharaldsen, Sr. Director of Marketing
Has Acer Therapeutics been receiving favorable news coverage?
Press coverage about ACER stock has trended somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acer Therapeutics earned a media sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 44.78 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Acer Therapeutics' major shareholders?
Acer Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Heartland Advisors Inc. (0.74%) and Neuberger Berman Group LLC (0.27%). Company insiders that own Acer Therapeutics stock include Steve Aselage and Timothy C Barabe. View Institutional Ownership Trends for Acer Therapeutics.
Which major investors are buying Acer Therapeutics stock?
How do I buy shares of Acer Therapeutics?
Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acer Therapeutics' stock price today?
One share of ACER stock can currently be purchased for approximately $18.22.
How big of a company is Acer Therapeutics?
Acer Therapeutics has a market capitalization of $140.95 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-14,190,000.00 in net income (profit) each year or ($3.84) on an earnings per share basis. Acer Therapeutics employs 6 workers across the globe.
How can I contact Acer Therapeutics?
Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]
MarketBeat Community Rating for Acer Therapeutics (ACER)
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
Acer Therapeutics (NASDAQ:ACER) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Acer Therapeutics in the last 12 months. Their average twelve-month price target is $60.00, suggesting that the stock has a possible upside of 229.31%. The high price target for ACER is $70.00 and the low price target for ACER is $50.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $60.00 | $60.00 | $50.00 | N/A |
| Price Target Upside: | 229.31% upside | 226.09% upside | 195.68% upside | N/A |
Acer Therapeutics (NASDAQ:ACER) Consensus Price Target History
Acer Therapeutics (NASDAQ:ACER) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Acer Therapeutics (NASDAQ:ACER) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Acer Therapeutics (NASDAQ ACER) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 25.70%
Institutional Ownership Percentage: 8.17%
Acer Therapeutics (NASDAQ ACER) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/14/2017 | Steve Aselage | Director | Buy | 2,000 | $12.00 | $24,000.00 | |  |
| 11/18/2016 | Timothy C Barabe | Director | Sell | 14,914 | $0.55 | $8,202.70 | 20,719 | |
| 9/17/2014 | Timothy C Barabe | Director | Buy | 10,000 | $1.15 | $11,500.00 | | |
| 9/16/2014 | Neil K Warma | CEO | Buy | 10,000 | $1.11 | $11,100.00 | | |
| 12/18/2013 | Karthik Radhakrishnan | CFO | Buy | 8,000 | $1.70 | $13,600.00 | | |
| 12/18/2013 | Scott B Seaman | Director | Buy | 30,000 | $1.70 | $51,000.00 | | |
| 8/8/2013 | Karthik Radhakrishnan | CFO | Buy | 50,000 | $1.50 | $75,000.00 | | |
(Data available from 1/1/2013 forward)
Acer Therapeutics (NASDAQ ACER) News Headlines
| Source: |
|
Acer Therapeutics (NASDAQ:ACER) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Acer Therapeutics (NASDAQ:ACER) Income Statement, Balance Sheet and Cash Flow Statement
Acer Therapeutics (NASDAQ ACER) Stock Chart for Friday, May, 25, 2018
Loading chart…
